Endocrinology, Vol 134, 2283-2288, Copyright © 1994 by Endocrine Society

ARTICLES

The effects of raloxifene on tibia histomorphometry in ovariectomized rats

G Evans, HU Bryant, D Magee, M Sato and RT Turner
Department of Orthopedics, Mayo Clinic, Rochester, Minnesota 55905.

Tissue-specific estrogen agonists may be useful in protecting against osteoporosis and the increased risk of coronary heart disease in postmenopausal women with minimal undesired effects on reproductive tissues. The actions of the mixed estrogen agonist/antagonist raloxifene on selected estrogen target tissues were determined in ovariectomized (OVX) rats immediately postovariectomy. Five groups of 75-day-old Sprague-Dawley rats were studied; baseline controls, sham- operated controls, OVX controls, OVX animals treated with estrogen (0.1 mg 17 alpha-ethynyl estradiol/kg.day), and OVX animals treated with raloxifene (3 mg/kg.day). Fluorochrome labels were given on days 1, 28, and 34. The baseline controls were killed on day 2, and the remaining groups on day 35. Ovariectomy increased tibial longitudinal growth rate as well as measurements related to radial growth and cancellous bone turnover. Ovariectomy decreased cancellous bone area and uterine weight, and increased serum cholesterol, bone elongation, and radial bone growth. Estrogen treatment prevented these changes in OVX rats. Raloxifene prevented cancellous osteopenia as well as the changes in radial bone growth, bone resorption, and blood cholesterol, but was less effective in reducing cancellous bone formation and did not prevent uterine atrophy. These findings suggest that raloxifene is a target-specific, mixed estrogen agonist/antagonist. At the concentration studied, raloxifene had potent estrogenic activity on bone resorption and serum cholesterol, a lesser effect on bone formation, and minimal activity on uterine wet weight.

This article has been cited by other articles:

				K. E. Govoni, J. E. Wergedal, R. B. Chadwick, A. K. Srivastava, and S. Mohan Prepubertal OVX increases IGF-I expression and bone accretion in C57BL/6J mice Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1172 - E1180. [Abstract] [Full Text] [PDF]

				M. J. Perry, S. Gujra, T. Whitworth, and J. H. Tobias Tamoxifen Stimulates Cancellous Bone Formation in Long Bones of Female Mice Endocrinology, March 1, 2005; 146(3): 1060 - 1065. [Abstract] [Full Text] [PDF]

				O. Nilsson, J. Falk, E. M. Ritzen, J. Baron, and L. Savendahl Raloxifene Acts as an Estrogen Agonist on the Rabbit Growth Plate Endocrinology, April 1, 2003; 144(4): 1481 - 1485. [Abstract] [Full Text] [PDF]

				J. D. Sibonga, S. Lotinun, G. L. Evans, V. S. Pribluda, S. J. Green, and R. T. Turner Dose-Response Effects of 2-Methoxyestradiol on Estrogen Target Tissues in the Ovariectomized Rat Endocrinology, March 1, 2003; 144(3): 785 - 792. [Abstract] [Full Text] [PDF]

				K. M. Prestwood, M. Gunness, D. B. Muchmore, Y. Lu, M. Wong, and L. G. Raisz A Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2197 - 2202. [Abstract] [Full Text]

				Y. Ishimi, C. Miyaura, M. Ohmura, Y. Onoe, T. Sato, Y. Uchiyama, M. Ito, X. Wang, T. Suda, and S. Ikegami Selective Effects of Genistein, a Soybean Isoflavone, on B-Lymphopoiesis and Bone Loss Caused by Estrogen Deficiency Endocrinology, April 1, 1999; 140(4): 1893 - 1900. [Abstract] [Full Text]

				W. Khovidhunkit and D. M. Shoback Clinical Effects of Raloxifene Hydrochloride in Women Ann Intern Med, March 2, 1999; 130(5): 431 - 439. [Abstract] [Full Text] [PDF]

				M. Sato, G. Q. Zeng, E. Rowley, and C. H. Turner LY353381{middle dot}HCl: An Improved Benzothiophene Analog with Bone Efficacy Complementary to Parathyroid Hormone-(1-34) Endocrinology, November 1, 1998; 139(11): 4642 - 4651. [Abstract] [Full Text] [PDF]

				R. T. Turner, G. L. Evans, J. P. Sluka, M. D. Adrian, H. U. Bryant, C. H. Turner, and M. Sato Differential Responses of Estrogen Target Tissues in Rats Including Bone to Clomiphene, Enclomiphene, and Zuclomiphene Endocrinology, September 1, 1998; 139(9): 3712 - 3720. [Abstract] [Full Text] [PDF]

				J. D. Sibonga, H. Dobnig, R. M. Harden, and R. T. Turner Effect of the High-Affinity Estrogen Receptor Ligand ICI 182,780 on the Rat Tibia Endocrinology, September 1, 1998; 139(9): 3736 - 3742. [Abstract] [Full Text] [PDF]

				C. Logie, M. Nichols, K. Myles, J. W. Funder, and A. F. Stewart Positive and Negative Discrimination of Estrogen Receptor Agonists and Antagonists Using Site-Specific DNA Recombinase Fusion Proteins Mol. Endocrinol., August 1, 1998; 12(8): 1120 - 1132. [Abstract] [Full Text]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]

				R. P. Heaney and M. W. Draper Raloxifene and Estrogen: Comparative Bone-Remodeling Kinetics J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3425 - 3429. [Abstract] [Full Text] [PDF]

				M. A. Jimenez, D. E. Magee, H. U. Bryant, and R. T. Turner Clomiphene Prevents Cancellous Bone Loss from Tibia of Ovariectomized Rats Endocrinology, May 1, 1997; 138(5): 1794 - 1800. [Abstract] [Full Text] [PDF]

				S. G. Lundeen, J. M. Carver, M.-L. McKean, and R. C. Winneker Characterization of the Ovariectomized Rat Model for the Evaluation of Estrogen Effects on Plasma Cholesterol Levels Endocrinology, April 1, 1997; 138(4): 1552 - 1558. [Abstract] [Full Text] [PDF]

				J. M. Cavolina, G. L. Evans, S. A. Harris, M. Zhang, K. C. Westerlind, and R. T. Turner The Effects of Orbital Spaceflight on Bone Histomorphometry and Messenger Ribonucleic Acid Levels for Bone Matrix Proteins and Skeletal Signaling Peptides in Ovariectomized Growing Rats Endocrinology, April 1, 1997; 138(4): 1567 - 1576. [Abstract] [Full Text] [PDF]

				R. F. Kauffman, W. R. Bensch, R. E. Roudebush, H. W. Cole, J. S. Bean, D. L. Phillips, A. Monroe, G. J. Cullinan, A. L. Glasebrook, and H. U. Bryant Hypocholesterolemic Activity of Raloxifene (LY139481): Pharmacological Characterization as a Selective Estrogen Receptor Modulator J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 146 - 153. [Abstract] [Full Text]